>How did Novartis get into the lucentis program? Why didn't Roche handle the eu markets?<
NVS has a longstanding presence in ophthalmology (dating back to the Ciba-Geigy days), while Roche has never been a player of consequence in the field.
Roche had the first option on Lucentis outside the U.S., as they do with every drug from DNA, but they wisely declined.
Market Data 
Markets 
AI
